Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | GALR3 | O60755 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9063346 | 0.94 | TSHR (0.44) | TSHRRECQLHTTMAPTHPGD | |
| SCHEMBL7132351 | 0.82 | L3MBTL1 (0.46) | HTTHPGDALDH1A1LMNAHSD17B10 | |
| SCHEMBL11394808 | 0.78 | TSHR (0.50) | TSHRRECQLHTTMAPTHPGD | |
| SCHEMBL2634202 | 0.76 | TSHR (0.48) | TSHRRECQLHTTMAPTHPGD | |
| SCHEMBL1164361 | 0.76 | HTT (0.50) | TSHRRECQLHTTMAPTHPGD | |
| SCHEMBL625352 | 0.76 | TSHR (0.48) | TSHRRECQLHTTMAPTHPGD | |
| SCHEMBL5517767 | 0.76 | HPGD (0.54) | TSHRHTTMAPTHPGDALDH1A1 | |
| SCHEMBL3116490 | 0.76 | TSHR (0.44) | TSHRRECQLHTTMAPTHPGD | |
| SCHEMBL24254327 | 0.74 | HPGD (0.58) | TSHRHTTMAPTHPGDALDH1A1 | |
| SCHEMBL10536613 | 0.74 | TSHR (0.47) | TSHRRECQLHTTMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 743 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117050053-A | Novel thiophene antitumor compound and preparation method and application thereof | 北京中医药大学 | 2023-11-14 | — | — | CN | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| CN-117659017-B | TRPML1/2 modulator compound, pharmaceutical composition, preparation method and application thereof | 北京华益健康药物研究中心 | 2026-05-15 | — | — | CN | disclosed |
| US-20250376452-A1 | 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof | ENANTA PHARM INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-12384753-B2 | 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4573088-A1 | HETEROCYCLE RBM39 MODULATORS | Recursion Pharmaceuticals, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20250115569-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | LARIO THERAPEUTICS LTD (GB) | 2025-04-10 | — | — | US | disclosed |
| CN-119684198-A | Preparation method of sulfonyl alanine | 重庆医科大学 | 2025-03-25 | — | — | CN | disclosed |
| CN-119630658-A | Heterocyclic RBM39 modulators | 递归医药公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-114206335-B | KCNT1 inhibitors and methods of use | 普拉克西斯精密药物股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-119585247-A | Bicyclic heterocyclic amide inhibitors of nav1.8 for the treatment of pain | 赛特温治疗公司 | 2025-03-07 | — | — | CN | disclosed |
| WO-1996031492-A1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-10-10 | — | — | WO | disclosed |
| EP-0699191-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-03-06 | — | — | EP | disclosed |
| WO-1994027979-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | IMMUNOPHARMACEUTICS, INC. (US) | 1994-12-08 | — | — | WO | disclosed |
| EP-0340010-B1 | Heterocyclic nitromethane derivatives | ICI PLC (GB) | 1994-08-24 | — | — | EP | disclosed |
| US-5102905-A | For treating side effects of diabetes and galactosemia | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-04-07 | — | — | US | disclosed |
| CN-1037339-A | Heterogeneous ring compound | ICI PLC (GB) | 1989-11-22 | — | — | CN | disclosed |
| EP-0340010-A2 | Heterocyclic nitromethane derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-11-02 | — | — | EP | disclosed |
| EP-0042731-B1 | LARVICIDES, INSECTICIDES, ACARICIDES AND MITICIDES, PROCESSES FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM | Pfizer Limited (GB) | 1984-12-05 | — | — | EP | disclosed |
| EP-0042731-A1 | Larvicides, insecticides, acaricides and miticides, processes for preparing them and compositions containing them | Pfizer Limited (GB) | 1981-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376452-A1 | 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof | HSD17B1, HSD17B13, HSD17B3 | TSHR 3945/4885RECQL 1952/4885HTT 3705/4885 |
| US-20250115569-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | CACNA1A, CACNA1E, CACNA1S | TSHR 1923/4885RECQL 781/4885HTT 499/4885 |
| US-12384753-B2 | 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof | HSD17B1, HSD17B13, HSD17B3 | TSHR 3945/4885RECQL 1952/4885HTT 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.